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ABSTRACT  
Interleukin 37 (IL-37), a member of the IL-1 family, broadly reduces innate 
inflammation as well as acquired immunity.  However, it remains unknown whether the 
anti-inflammatory properties of IL-37 include the central nervous system.  In the present 
study, we subjected mice to spinal cord compression injuries.  We compared mice that 
are transgenic for human IL-37 (hIL-37tg) to wild-type (WT) mice; we also treated WT 
mice with recombinant IL-37.  In hIL-37tg mice, the expression of IL-37 was barely 
detectable in the uninjured cords, but strongly induced 24 and 72 hours after the injury.  
Compared to WT mice, hIL-37tg mice exhibited increased myelin and neuronal sparing 
and protection against locomotor deficits including a 2.5 fold greater speed under forced 
treadmill challenge.  Reduced levels of cytokines, such as an 80% reduction in IL-6, 
were observed in the injured cords of hIL-37tg mice, as well as, lower numbers of 
blood-borne neutrophils, macrophages and activated microglia.  We treated WT mice 
with single intraspinal injection of either full-length or processed recombinant IL-37 
after the injury.  We observed that IL-37-treated mice had significantly enhanced 
locomotor skills in an open field using the BMS score test, as well as, supported faster 
speed on a mechanical treadmill.  Both forms of recombinant IL-37 led to similar 
beneficial effects on locomotor recovery after the injury.  Overall, this study presents 
novel data indicating that IL-37  suppresses inflammation in a clinically relevant model 
of spinal cord injury, and concludes that recombinant IL-37 may have therapeutic 
potential for the treatment of acute spinal cord injuries.  
  
 Significance Statement  
Spinal cord injuries often result in severely impaired locomotor, sensory and autonomic 
function.  Although inflammation contributes to the physiopathology of spinal cord 
injury, several clinical trials of high doses of dexamethasone or methylprednisolone 
have not resulted in improved recovery of function.  IL-37, a member of the IL-1 
family, exerts broad anti-inflammatory effects in several mouse models of inflammatory 
diseases.  We report here that mice expressing human IL-37 exhibit reduced 
inflammation in the central nervous system and resulted in significantly improved 
functional disabilities following spinal cord injury.  The administration of recombinant 
forms of human IL-37 enhances motor skills after spinal cord injury, suggesting that 
IL-37 could provide a new therapeutic approach to limit the harmful effects of 
inflammation in neurological conditions. 
\body 
INTRODUCTION 
The inflammatory response plays an essential role in protecting after injury or 
invasion by microorganisms (1, 2).  Regardless of the tissue, unless regulated, 
inflammation can become chronic and result in tissue damage and loss of function (1, 
2).  This is particularly the case of spinal cord injury.  After spinal cord contusion or 
compression injury, there is a rapid initiation of inflammation in rodents and in humans 
(2).  This response is orchestrated by endogenous microglial cells, and by circulating 
leukocytes, especially monocytes and neutrophils, which invade the lesion site during 
the first hours and days following injury (2-4).  Although these cells are required for the 
clearance of cellular and myelin debris, they also release cytokines and cytotoxic 
factors, which are harmful to neurons, glia, axons and myelin, resulting in secondary 
damage to adjacent regions of the spinal cord that had been previously unaffected by the 
insult (2, 5, 6).  Indeed, it is currently well accepted that inflammation is a major 
contributor to secondary cell death after spinal cord injury (SCI).  The damaging effects 
of inflammation are more pronounced in the central nervous system (CNS) than in other 
tissues because of the limited capacity for axon regeneration and replenishment of 
damaged neurons and glial cells, which leads to irreversible functional disabilities (7, 
8).  Therefore, targeting inflammation is a valuable approach to promote 
neuroprotection and limit functional deficits in SCI. 
Cytokines are key players in the initiation, progression and suppression of 
inflammation.  Although several members of the interleukin-1 (IL-1) family are pro-
inflammatory (9, 10), IL-37 has broad suppressive effects on innate inflammation and 
acquired immunity (11-14).  Since a complete open reading frame for the mouse 
homolog of IL-37 has not been found, it was necessary to generate a strain of transgenic 
mice expressing human IL-37 (hIL-37tg mice).  These mice are protected against 
endotoxin shock, colitis, hepatitis and myocardial infarction (9, 13, 15-18).  However, a 
role for IL-37 after CNS trauma remains unexplored.  In the current study, we subjected 
hIL-37tg to SCI and studied subsequent functional impairments in comparison to wild 
type (WT) mice.  We also administered recombinant IL-37 to WT mice in order to 
provide a rationale for clinical use of IL-37 as a therapeutic.  We provide direct 
evidence for the first time that IL-37 exerts marked anti-inflammatory properties for the 
contused spinal cord, and confers protection from tissue damage and functional loss.  
 
RESULTS 
hIL-37tg mice exhibit reduced functional deficits and tissue damage after SCI  
As shown in Figure 1A, hIL-37tg mice displayed significant improvement in 
locomotor recovery after SCI.  There were significant improvements in BMS scores 
starting at day 7 after injury, and remaining significantly enhanced for the following 3 
weeks (Fig. 1A).  At the 28th day post-injury (dpi), all WT mice showed extensive 
ankle movement, but only 50% of these mice showed plantar paw placement but no 
weight-bearing stepping (BMS score 2.5).  In contrast, all hIL-37tg mice showed 
extensive ankle movement, plantar paw placement with weight support, and the 
majority displayed occasional stepping (BMS score 3.8) (Fig. 1A). Moreover, hIL-37tg 
mice performed ~2.5 fold faster locomotion on the treadmill than WT mice (Fig. 1B), 
further demonstrating the protective effect of IL-37 against functional loss in SCI.  
We then assessed whether the improvement in motor skills of hIL-37tg mice was 
associated with reduced secondary tissue damage after SCI.  Histological sections from 
the injury epicenter stained with luxol fast blue (LFB) revealed enhanced myelin 
sparing in hIL-37tg compared to WT mice (Fig 1C, D).  Prevention of myelin loss by 
transgenic expression of IL-37 was evident at the lesion epicenter and at distances up to 
800 µm caudal to the injury (Fig 1C, D). Assessment of neuronal sparing in the ventral 
horns also demonstrated attenuated neuronal loss in hIL-37tg (Fig. 1E, F). Spinal cord 
sections stained against NeuN revealed that hIL-37tg mice had greater numbers of 
neurons at several regions rostral and caudal to the injury epicenter in hIL-37tg mice 
(Fig. 1 E, F). 
Since infiltrating macrophages inhibit axonal outgrowth by releasing soluble 
factors and by cell-cell interaction (19, 20), we sought to evaluate whether there was 
enhanced axonal regeneration in hIL-37tg mice after complete spinal cord transection.  
hIL-37tg and WT mice presented complete hindlimb paralysis after the injury and 
lacked functional improvement at 10 weeks post-lesion (BMS score 0).  Histological 
assessment of sagittal spinal cord tissue sections revealed that transgenic expression of 
IL-37 did not led to regeneration of axons beyond the transection site. Similarly, axonal 
counts at rostral distances to the injury did not reveal any difference between hIL-37tg 
and WT mice (Fig. 2), suggesting that IL-37 did not promote regeneration/sprouting of 
corticospinal axons (Fig. 2).  Overall, these data provide evidence that IL-37 confers 
protection from functional disabilities and secondary tissue damage after spinal cord 
contusion injury, but does not promote axonal outgrowth of the corticospinal tract. 
 
IL-37 is induced in hIL-37tg mice after SCI 
Since hIL-37tg mice were markedly protected against functional disabilities and 
tissue loss after SCI, we studied the inflammatory response in hIL-37tg mice.  We first 
assessed the expression profile of IL-37 in the spinal cord of hIL-37tg mice determined 
by PCR.  Expectedly, IL-37 was not present in the intact or damaged spinal cord 
obtained from WT mice.  hIL-37tg mice exhibited a low level of constitutive expression 
of IL-37 in the spinal cord.  Low levels of constitutive IL-37 expression in the 
transgenic mice have also been observed in the colon, skin, circulating leukocytes or in 
cell lines transfected with IL-37 (11, 13, 16).  The low levels are due to the instability 
sequence in human IL-37 (14). However, after the contusion injury, induction of IL-37 
in the spinal cord parenchyma was observed (Fig. 3).  IL-37 expression profile occurred 
at 2 peaks of expression; after 12 hours and at day 3 post-injury, when the levels of IL-
37 increased ~17 and ~35 fold, respectively (Fig. 3).  The early peak of IL-37 coincides 
with the induction of cytokines in the injured spinal cord 6-24 hours post-injury (Fig. S1 
and Fig. S2), whereas the latter correlates with the infiltration of blood monocytes (day 
3) (2).  
 
Inhibition of cytokine and chemokine expression after SCI 
We next sought to examine whether the early increase in IL-37 modulated gene 
expression of cytokines in the contused spinal cord.  Injured spinal cords harvested at 12 
and 24 hours post-contusion, which are time periods when the protein levels of most 
cytokines and chemokines reach maximal concentrations after SCI (2).  We evaluated 
the protein levels of 32 cytokines in the injured spinal cord.  At 12 hours post-injury, 
cytokine levels were unchanged in hIL-37tg relative to WT mice (Fig. S2).  However, at 
24 hours post-injury, we observed a significant reduction in the expression of 23 out of 
the 32 cytokines in hIL-37tg mice (Fig. S1).  Moreover, the expression of IL-3, which 
was detected at low levels in the spinal cord homogenates of WT mice (0.56±0.03 
pg/mg protein), was undetectable in hIL-37tg mice (<0.45 pg/mg protein).  The levels 
of 6 cytokines (LIF, M-CSF, IL-2, IL-5, IL-15, and eotaxin) did not change in IL-37tg 
mice, whereas the expression of IL-4, IL-12p40 was not detected in the contused spinal 
cord of both experimental groups (Fig. S1).  
We next evaluated the accumulation of inflammatory cells between WT mice 
and hIL-37tg mice following SCI. At day 1 post-injury, when granulocyte infiltration 
reaches peak levels, the spinal cord of hIL-37tg mice showed ~40% reduction in the 
number of granulocytes (Fig. 4).  There were no differences in the cell counts for 
activated microglia, blood borne macrophages, CD4 and CD8 T cell, at this time point 
(Fig. 4).  
Seven days post-injury, when the accumulation of activated microglia and 
macrophages reaches peak levels in the injured spinal cord and accounts for ~80% of 
total immune cells, spinal cords from hIL-37tg mice exhibited significantly lower 
numbers of these two cell subsets (Fig. 5).  The number of granulocytes, which were 
reduced by 90% compared to day 1, were slightly increased in hIL-37tg, but did not 
reach statistical significance, whereas counts for CD4 and CD8 lymphocytes were 
unchanged (Fig. 3).  We also assessed whether IL-37 modulated macrophage and 
microglia polarization after SCI.  However, FACS analysis from contused spinal cords 
revealed no differences in IL-37tg mice for the expression of CD16/32 and CD206 on 
microglia (CD16/32: 76.2±4.2 vs 74.6±3.8; CD206: 14,1±3.1 vs 15.2±3.1 in WT and 
IL37tg, respectively) or macrophages (CD16/32 82.2±6.7 vs 79.4±5.3; CD206 14.5±1.9 
vs 16.6±3.2 in WT and IL-37tg, respectively), two known markers of M1 and M2 
activation, respectively.  
 
Intralesional administration of recombinant IL-37 improves functional outcomes 
after SCI 
To assess a therapeutic use of IL-37 in SCI, we administered recombinant forms 
of human IL-37 (rlL-37) to determine possible beneficial effects in SCI.  We first tested 
the IL-37 precursor (full-length of IL-37 isoform b), as previous studies have shown 
efficacy in vivo (21) and in vitro (22).  We also administered a processed form of IL-37 
with the N-terminus at valine 46 (22, 23).  Since the blood brain barrier prevents the 
entry of most molecules into the CNS, we infused rIL-37 into the lesion site 5 minutes 
after contusion injury, using a glass capillary (30µm diameter).  As shown in Fig. 6A, 
intraspinal injection of either full-length or processed rIL-37 significantly enhanced 
locomotor recovery in the BMS score, starting at day 10 post-injury. At day 28, mice 
injected with saline had a BMS score of 1.6, which corresponds to slight or extensive 
movement of the ankle. However, treatment with full-length rIL-37 improved the BMS 
score in 1 point (Fig. 6A). rIL-37-treated mice showed extensive movement of the ankle 
and most of them also displayed plantar paw placement in at least one paw, but no 
stepping.  Moreover, treatment with full-length rIL-37 increased in 50% the speed that 
mice were able to achieve on a treadmill (Fig. 6B), further suggesting the beneficial 
effects of rIL-37 in preventing functional deficits after SCI. Overall, both forms of 
rIL-37 led to similar beneficial effects on motor skills (Fig. 6).  
 
DISCUSSION 
Although IL-37 is lacking in mice, hIL-37tg mice are protected against several 
inflammatory challenge.  Using the hIL-37tg mouse, previous studies have consistently 
demonstrated the suppressive properties of IL-37 on inflammation (11, 13, 16).  
However, whether IL-37 exerts a similar anti-inflammatory effect in the CNS trauma 
remained unknown.  Here we demonstrate for the first time that IL-37 suppresses 
inflammation and limits locomotor deficits and tissue damage in spinal cord contusion 
injury in the mouse.  This conclusion is based on observations in IL-37tg mice as well 
as in WT mice treated with either recombinant IL-37 precursor or processed IL-37.  
In hIL-37tg mice, the expression is regulated by a constitutive cytomegalovirus 
(CMV) promoter (13) and thus, it should induce the expression in all cells. However, 
constitutive expression of IL-37 in the spinal cord is low owing to the presence of an 
instability sequence that limits the half-life of the IL-37 transcript (14).  This has been 
also shown in other models using these mice (11, 13, 16).  However, upon inflammatory 
conditions, such as the trauma to tissue, there is activation of inflammatory components, 
which increases the half-life of IL-37 mRNA and allows for translation of the protein 
IL-37. IL-37 mRNA stability is apparently regulated by instability elements present in 
exon 5, as exon 5 deletion can significantly increase mRNA stability of both IL-37b and 
IL-37c. A similar mRNA stabilization upon LPS stimulation can be observed for IL-18  
(14). We observed that mRNA levels were induced 12 hours after SCI and then a 
secondary increase occurs 3 days after the injury.  It remains unknown, however, 
whether endogenous IL-37 is expressed in human SCI.   Cytokines such as IL-1β, TLR 
agonist and TGFβ are known to induce IL-37 in vitro (13).  Cytokine expression reaches 
maximal levels in the spinal cord within 6-24 hours post-injury (2), which may account 
for the first peak of IL-37.  Although IL-37 is mainly expressed in macrophages in hIL-
37tg mice after several inflammatory challenges (13, 16, 24), endogenous glial cells 
(astrocytes and microglia) are probably the early source of IL-37 due to the low amount 
of infiltrated leukocytes at this time point. However, the later expression peak of IL-37 
(3dpi) coincides with the entrance of blood borne monocytes into the spinal cord, 
suggesting that macrophages are the main source of the second peak of IL-37 (2).  
IL-37 reduces the expression of several pro-inflammatory cytokines in cell 
cultures and in different inflammatory disorders (13, 15, 16, 18, 25).  We also found 
that IL-37 attenuated the protein levels of most pro-inflammatory cytokines evaluated in 
contused spinal cord, IL-6 being most markedly effected.  The capacity of IL-37 to 
reduce cytokine production after SCI impacted on the infiltration and activation of 
immune cells.  Indeed, IL-37 reduced the recruitment of neutrophils and macrophages 
into the injured spinal cord, but also the activation state of the microglia.  However, 
IL-37 did not affect the infiltration of T cells.  
Regardless of the species or type of SCI, anti-inflammatories or myeloid cell 
depletion consistently reveal reduced tissue damage and greater functional outcomes (2, 
3).  Here we show that hIL-37tg mice exhibited enhanced locomotor function that was 
associated with attenuated tissue damage after SCI.  Blood borne monocytes infiltrating 
into the injured spinal cord mediate axonal retraction (19, 20) and this deleterious effect 
is due products released by macrophages or by integral macrophage membrane proteins, 
which inhibit the growth and guidance of axons (19, 20).  Other inhibitory molecules 
include chondroitin sulphate proteoglycans, Nogo, Ephrins and semaphorins, which are 
expressed at the lesion site by astrocytes, oligodendrocytes and some precursor cells (7).  
There is also a limited ability of adult CNS neurons to switch on the intrinsic 
regeneration machinery after axotomy (26).  However, despite reduced macrophage 
numbers in spinal cords of hIL-37tg mice, axonal outgrowth was not observed, as these 
other factors, which hamper the ability of axons to regenerate in the injured CNS, may 
not be altered in the IL-37tg mouse.  Therefore, our data indicate that attenuation of 
inflammation in the IL-37tg mouse did not overcome the extrinsic and intrinsic factors 
that curtail the relatively limited regenerative potential of injured corticospinal axons. It 
is possible that increasing the dosing of recombinant IL-37 could enhance axonal 
outgrowth of other motor or sensory tracts with better regeneration capabilities. 
Once synthesized following activation, up to 30% of the IL-37 precursor is 
cleaved intracellularly by activated caspase-1 and translocates to the nucleus, most 
likely in association with Smad3 (13, 17). Indeed, the anti-inflammatory effects of 
IL-37 are abolished in LPS-stimulated macrophages when incubated with caspase-1 
inhibitors, or when the caspase-1 site (D20) is mutated, and cannot translocate to the 
nucleus (27).  Similarly, in vivo studies also reveal that the anti-inflammatory actions of 
IL-37 are lost when Smad3 is silenced after LPS challenge (13).  
On the other hand, the precursor form of IL-37 is released from human 
monocytes, or cell lines transfected with IL-37 following LPS stimulation (13).  The 
release of IL-37 is, however, independent on caspase-1 cleavage at D20 (27).  The 
administration of neutralizing antibodies against IL-37 enhances cytokine production in 
in vitro and in vivo, highlighting the extracellular anti-inflammatory function of IL-37 
(22, 27).  These observations are further supported by studies showing the ability of 
recombinant IL-37 protein to reduce cytokine production (22).  Extracellular IL-37 
carries out its anti-inflammatory actions by recruiting the decoy IL-1R8 to the 
IL-18Rα/IL-37 complex (28-30).  Administration of recombinant IL-37 improves 
functional recovery after SCI, indicating that extracellular IL-37 is sufficient for its 
beneficial effects in the CNS.  Nevertheless, we cannot rule-out the possibility that the 
translocation of IL-37 to the nucleus is also playing a role in the transgenic mouse and 
also in the human.  
It is likely that processing of the IL-37 precursor appears to take place 
extracellularly.  Edman degradation of supernatants from cells lines transfected with 
IL-37b revealed a processed form starting at valine 46 (IL-37V46-218) (23).  Both full 
length and processed IL-37 exhibit anti-inflammatory effects (22).  We observed that 
both IL-37 forms exert similar beneficial effects on functional outcomes after SCI, 
suggesting that the IL-37 precursor may be processed when administered in the injured 
spinal cord. 
In summary, recombinant IL-37 prevents functional deficits and secondary 
tissue damage in SCI suggesting a potential clinical application.  This is the first report 
suggesting that IL-37 could be an effective therapy during the acute phase after SCI, for 
which there is currently no effective treatment. 
 
MATERIALS AND METHODS 
Animals. Experiments were performed in adult (8-10 weeks) female mice expressing the 
human form of IL-37 (hIL-37tg) or C57Bl/6 mice (Charles River). After SCI, motor skills 
were assessed in hIL-37tg mice, WT and WT mice treated with recombinant human IL-
37 (r-IL-37). SI contains details about SCI models, r-IL-37 delivery, and functional 
assessment. 
Tissue processing. Spinal cords were cut on a cryostat and stained for assessing neuron 
survival, myelin sparing and axonal regeneration. Moreover, spinal cords were processed 
for RNA, cytokine protein level analysis and for FACS analysis. For more detail, see SI. 
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FIGURE LEGENDS 
Figure 1. hIL-37-tg mice show enhanced functional outcomes and reduced tissue 
damage after SCI.  (A) Locomotor skills assessed in the 9-point Basso Mouse Scale 
(BMS) and (B) on a treadmill.  (C) Myelin sparing at various distances rostral and 
caudal to the injury epicenter. (D) Representative micrographs showing myelin sparing 
at the injury epicenter in section stained against luxol fast blue from WT and hIL-37tg 
mice. (E) Ventral horn neuron survival at various distances rostral and caudal to the 
injury epicenter. (F) Representative micrographs showing sparing of ventral horn 
neurons in WT and hIL-37tg mice in sections stained against NeuN at 200 µm rostral to 
the injury epicenter. The area outlined in the box is shown in higher magnification in 
panels (insert). Data are expressed as mean ±SEM. (*p<0.05; two-ways RM-ANOVA, 
Bonferroni’s post hoc test in A, C and D; t-test in B; n=8 per group). 
 
Figure 2.  hIL-37tg expression does not promote axonal regeneration. (A) BDA-
labelled corticospinal axons at different distances to the transection site. (B-C) Low 
magnification images of complete transected spinal cord showing BDA-labelled 
corticospinal fibers in WT (B) and hIL-37tg mice (C). Lines define the transection site. 
L=lesion. Data are expressed as mean ±SEM. (*p<0.05; one-way ANOVA, 
Bonferroni’s post hoc test; n=8 per group). 
 
Figure 3. Expression of IL-37 after SCI.  Time course of IL-37 transcripts in the spinal 
cord of hIL-37tg mice after contusion injury (*p<0.05; one-way ANOVA, Bonferroni’s 
post hoc test; n=4 per time point). 
 
Figure 4.  Spinal cord immune cell counts at day 1 post-injury. (A-F) Representative 
density plots of FACS analysis showing myeloid cells and microglia (A, B), 
macrophages (CD45high, CD11b+, F4/80+) (C, D), and granulocytes (CD45high, 
CD11b+, Gr1high) (E, F) in the spinal cord of WT and hIL-37tg mice. (G) Graph 
showing quantification of the different immune cell populations in the injured spinal 
cord. Data are expressed as mean ±SEM. (*p<0.05; t-test; n=4 per group). 
 
Figure 5. Recruitment of immune cells within the spinal cord at day 7 post-injury. (A-
F) Representative density plots of FACS analysis showing myeloid cells and microglia 
(A, B), macrophages (CD45high, CD11b+, F4/80+) (C, D), and activated microglia 
(CD45low, CD11b+, F4/80+) (E, F) in the spinal cord of WT and hIL-37tg mice. (G) 
Graph showing quantification of the different immune cell populations in the injured 
spinal cord. Data are expressed as mean ±SEM. (*p<0.05 *p<0.001; # p=0.001; t-test; 
n=4 per group). 
 
Figure 6. Infusion of recombinant human IL-37 promotes functional recovery after 
spinal cord injury. Locomotor performance of C57BL/6 mice treated with intraspinal 
injection of saline, full length (IL-371-218) or processed form of IL-37b (IL-37V46-218) 
after spinal cord injury using the BMS score scale (A) and (B) treadmill. Data are 
shown as mean ±SEM. (*p<0.05; two-way RM-ANOVA, Bonferroni’s post hoc in A 
and t-test in B); n=14 for saline, n=9 for rIL-371-218 and rIL-37V46-218). 
 
SUPPORTING INFORMATION 
 
MATERIALS AND METHODS   
Surgical procedure 
All surgical procedures were approved by the Universitat Autònoma de Barcelona Animal 
Care Committee and followed the guidelines of the European Commission on Animal Care. 
Adult (8-10 weeks old) female C57BL/6 mice (Charles River) and hIL-37tg mice (13) were 
anesthetized with ketamine (90 mg/kg, i.m.) and xylazine (10 mg/kg, i.m.). After performing 
a laminectomy at the 11th thoracic vertebrae, the exposed spinal cord was contused with a 
force of 60 kdynes using the Infinite Horizon Impactor device (Precision Scientific 
Instrumentation) (31) or was completely transected using a microscalpel. At 56 days after 
complete spinal cord transection, corticospinal tract was labelled by injecting a 10% solution 
of the axonal tracer biotinylated dextran amine (BDA) in the sensory-motor cortex (32). 
Administration of recombinant human IL-37 protein (b isoform) was performed intraspinally 
by means of a glass capillary (30 µm internal diameter, Eppendorf, Hamburg, Germany) 
coupled to a 10 ml Hamilton syringe (Hamilton #701, Hamilton Co, Reno, NV, USA).  1 μl 
of saline, saline containing 100 ng of full length (rIL-371-218) or recombinant human IL-37V46-
218 was injected into injured spinal cord at the lesion site 5 minutes after lesion. Injections 
were made at a perfusion speed of 2 µl/min controlled by an automatic injector (KDS 310 
Plus, Kd Scientific, Holliston, MA, USA), and the tip of the glass capillary was maintained 
inside the cord tissue 3 min after each injection to avoid liquid reflux. 
RNA isolation, reverse transcription and real-time PCR 
Mice were perfused with sterile saline and 5mm length of uninjured spinal cord was removed. 
Tissue was homogenized with QIAzol lysis reagent (Qiagen) and RNA extracted using 
RNeasy Lipid Tissue kit (Qiagen), according to the manufacturer’s protocol. RNA was 
treated with DNaseI (Qiagen) to eliminate genomic DNA contamination. 1 μg of obtained 
RNA was primed with random hexamers (Promega) and reverse transcribed using 
Omniscript RT kit (Qiagen). RNase inhibitor (Roche) was added (1 U/μl final concentration) 
to avoid RNA degradation. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
as a housekeeping gene 
Cytokine Protein Expression 
Mice were perfused with sterile saline and a 5 mm length of spinal cord centered on the lesion 
was collected at 12 and 24h after surgery from hIL-37tg and WT mice and snap-frozen.  
Spinal cords were homogenized and protein concentration was determined using the DC 
Protein Assay (Bio-Rad).  Samples were concentrated to 4 µg/µl using MicroCon 
centrifugation filters (Millipore) to ensure equal amounts of protein. The protein levels of 32 
cytokines and chemokines were then analyzed using the Milliplex MAP Mouse 
Cytokine/Chemokine magnetic bead panel (Millipore) on a Luminex (Millipore) as per 
manufacturers’ protocol.   
Flow Cytometry 
Immune cells from the injured spinal cord were analyzed by flow cytometry at 1 and 7 dpi 
as described previously (33).  Briefly, spinal cords were cut in small pieces, passed through 
a cell strainer of 70 µm (BD Falcon) using saline and the cell suspension was centrifuged at 
300g for 10 minutes at 4ºC.  The pellet was resuspended and centrifuged for a second time.  
Samples were divided, and cells alone and isotype-matched control samples were generated 
to control for nonspecific binding of antibodies and for auto-fluorescence.  The following 
antibodies were also purchased from eBioscience: CD45-PerCP, CD11b-PE-Cy7, Gr1-FITC, 
F4/80-APC or PE, CD3-FITC, CD4-APC, CD8-APC, CD19-PE.  After 30 min of incubation 
with combinations of antibodies at 4°C, the samples were washed and fixed in 1% 
paraformaldehyde.  The following combination of marker was used to identify activated 
microglia (CD45low, CD11b+, F4/80+), granulocytes as (CD45high, CD11b+ , F4/80-, Gr-1high 
),   macrophages (CD45high, CD11b+, F4/80+), CD4 T-Cells (CD45+, CD11b-, CD3+, CD4+) 
and CD8 T-Cells (CD45+, CD11b, CD3+, CD8+) (31).  In addition, microglia and 
macrophages were further differentiated based on CD16/32 and CD206 and to assess M1 and 
M2 polarization, respectively.  Cells were analyzed using FlowJo® software on a 
FACSCanto flow cytometer (BD Biosciences). 
Functional assessment 
Locomotor recovery was evaluated at 1, 3, 5, 7, 10, 14, 21 and 28 dpi in an open-field 
test using the nine-point Basso Mouse Scale (BMS) (34), which was specifically developed 
for locomotor testing after contusion injuries in mice. The BMS analysis of hindlimb 
movements and coordination was performed by two independent and blinded assessors and 
a consensus score taken.  In addition, at the end of the follow up (day 28 post-injury), the 
highest locomotion speed of the mice was evaluated on a belt of a motorized treadmill.  
Briefly, each mouse was allowed to explore the treadmill compartment for 5min, with the 
motor speed set to zero.  Then, speed was increased 2 cm/s every 5 seconds until the animal 
was not able to maintain the speed. The maximum speed at which each mouse was able to 
achieve for 5 seconds was recorded. 
Histology 
At 28 days post-injury mice were perfused with 4% paraformaldehyde in 0.1M-
phosphate buffer (PB) at 12h, 3 and 28 dpi.  A 5mm length of spinal cord containing the 
lesion site was removed, cryoprotected with 30% sucrose in 0.1M PB at 4ºC, and 6 series of 
10µm thick section were picked up on glass slides.  Adjacent sections on the same slide were 
therefore 100µm apart.  For demyelination analyses, sections were stained with Luxol fast 
blue (LFB) (Sigma).  After graded dehydration, sections were placed in a 1 mg/ml LFB 
solution in 95% ethanol and 0.05% acetic acid overnight at 37ºC. Sections were then washed 
in 95% ethanol and distilled water before place them into a solution of 0.5 mg/ml Li2CO3 in 
distilled water for 1 min at RT.  After washes in distilled water, sections were dehydrated 
and mounted in DPX mounting media (Sigma). For neuronal assessment, sections were 
incubated overnight at 4ºC with biotinylated antibodies against NeuN. After several washes 
in PBS, sections were stained using the ABC kit (Vector labs) then a coverslip was applied 
in DPX mounting media (Sigma). 
The epicenter of the injection or contusion injury impact was determined for each 
mouse spinal cord by localizing the tissue section with the greatest damage using LFB stained 
section.  Myelin sparing after SCI was calculated by delineating the spared LFB stained tissue 
area from images taken at x40 magnification at the injury epicenter, and every 200 µm rostral 
and caudal to the lesion site. Neuronal survival was assessed by manually counting the 
number of NeuN+ cells in high magnification (x400) images taken from the both ventral 
horns at the injury epicenter and very 200 µm rostral and caudal to the lesion site.  The NIH 
ImageJ software was used to quantify all these histological parameters. 
10 days after BDA tracer injections (66 days post-injury) mice were perfused, and the 
transected spinal cord harvested and cut on 20 µm thick sagittal sections as described above.  
Visualization of corticospinal fibers of done by incubating the spinal cord sections with Alexa 
594-conjugated streptavidin. Pictures from the spinal cord  covering the transection lesion 
and up 3000 µm rostral were taken at x200 magnification, and then merged into collages 
using the Photoshop software. Only sections that contained BDA-labeled fibers were 
acquired. The number of pixels of BDA-labeled fibers with a dorso-ventral line was counted 
every 150 µm over the rostro-caudal axis using NIH software.   
 
FIGURES 
Fig. S1. Multiplex analysis of cytokine protein profiles from spinal cord of WT and hIL-37tg 
mice at 24 hours post-injury. Data are expressed as fold change vs WT mice (mean ±SEM).  
Fig. S2. Multiplex analysis of cytokine protein profiles from spinal cord of WT and hIL-37tg 
mice at 12 hours post-lesion. Data are expressed as fold change vs WT mice (mean ±SEM).  
 
 








